The Tau Next Generation (Tau NexGen) clinical trial will now be evaluating an anti-amyloid antibody in addition to an anti-tau antibody as a potential treatment for early onset Alzheimer’s disease, according to a press release. BioArctic and Eisai‘s investigational treatment lecanemab has been selected as the background anti-amyloid agent to be used for the first arm of…
The blood levels of two biomarkers of Alzheimer’s disease are significantly associated with changes in brain beta-amyloid deposits and cognitive function in early Alzheimer’s patients treated with lecanemab (BAN2401), according to a new analysis of data from a Phase 2b clinical trial. The results suggest that these blood biomarkers — p-tau181 and beta-amyloid fragments —…
An investigation vaccine for Alzheimer’s disease, ACI-35.030 by AC Immune, induced a potent production of antibodies against toxic forms of tau protein — a Alzheimer’s hallmark — in patients with early stage disease, interim results of an ongoing Phase 1b/2a trial show. “These promising results … will be invaluable as we work to further ACI-35.030’s clinical development…
At first glance, it’s a simple photo of eight small crochet works posted in three rows on a light-color backdrop and contained in a wooden frame. But there’s much more to it than that. The photo is a visual representation of the progressive effect of Alzheimer’s as put together by the daughter of the artist,…
A European Medicines Agency (EMA) committee has voted against approving Biogen’s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. The EMA’s Committee for Medicinal Products for Human Use, known as CHMP, is expected to issue a formal ruling based on this so-called negative trend vote after its meeting in mid-December. But the regulatory agency usually follows…
Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive and functional decline in Alzheimer’s patients, according to a recent data analysis of two Phase 3 clinical trials. The data, analyzed from around 7,000 blood samples collected from more than 1,800 patients who participated in the EMERGE…
AC Immune has announced it will extend its partnership with researchers at the University of Pennsylvania to further study the mechanisms underlying disease-causing changes in the transactive response DNA binding protein 43 kDa (TDP-43). Specifically, company researchers and those with the university’s Center for Neurodegenerative Disease Research at the Perelman School of Medicine are looking into what causes TDP-43…
The MassAITC project was recently launched to focus on using artificial intelligence (AI) to improve in-home care for older adults and others with Alzheimer’s disease, with the help of a five-year, $20-million grant from the National Institute on Aging, a part of the National Institutes of Health. MassAITC, which stands for Massachusetts AI and Technology…
The first patient has been recruited, in Finland, for Alzinova AB’s Phase 1b clinical trial testing its ALZ-101 vaccine for Alzheimer’s disease, the company announced. Alzinova AB, a Swedish biopharma company, is working to develop treatments for Alzheimer’s that specifically target amyloid-beta oligomers — chains of several single units (monomers) of the protein. The toxic…
A biological framework called the “microcompetition model” may explain why people infected with herpes simplex 1 (HSV1) are at increased risk of developing Alzheimer’s disease. “These dynamics explain the observed connection reported in many studies between the virus and Alzheimer’s disease, and provide a framework for further investigations,” researchers wrote. This idea was outlined in…
